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The morbidity and mortality caused by severe gramnegative bacterial infections that lead to subsequent sepsis and shock remain high. Two different approaches to improve outcome have been (1) to develop agents to decrease different aspects of the proinflammatory response and (2) to develop agents to bind to components of the bacterial cell envelope. This latter approach is based on the concept that substances in the cell membrane, including lipopolysaccharide (LPS), induce lethal toxicity.
Multiple studies have suggested that passively infused IgG directed to the O-polysaccharide side chain of LPS is highly protective in animal models of sepsis [1] [2] [3] [4] . These studies suggest that immunoglobulin directed to the gram-negative cell membrane might have therapeutic benefit in patients with sepsis. However, because of the large number of clinically relevant gram-negative bac-terial strains, it has been difficult to take practical advantage of this approach. This same approach was the basis for the attempted development of immunoglobulin directed to common epitopes in the LPS core [5] . However, although numerous studies have indicated that passively administered antisera raised to rough mutant bacterial vaccines that expose the core glycolipid (such as Escherichia coli J5 or Salmonella minnesota Re595) were protective, the active principle in these antisera remains unclear. Several clinical trials failed when performed with monoclonal antibodies apparently directed to the conserved lipid A moiety in the LPS core [6] . However, because these antibodies bound LPS only weakly [7] and nonspecifically [8] and did not neutralize the biological effects of LPS [7] , it is unknown whether an immunoglobulin preparation that binds with high affinity and neutralizes LPS from multiple gram-negative strains would be clinically beneficial.
Cationic antimicrobial protein of 18 kDa (CAP18), a cationic protein found in leukocytes, binds with high affinity to LPS and neutralizes most of its biological activities [9] . CAP18 belongs to the cathelicidin family of antimicrobial peptides in mammalian leukocytes and is a major protein of human neutrophils. Cathelicidins have a conserved N-terminal domain and a variable C-terminal domain that is responsible for antimicrobial activity [10] . The gene for CAP18 is expressed in lung epithelium [11] , as well as in several other tissues, including the bone marrow and testis [12] .
The C-terminal LPS-binding domains of CAP18 from numerous species have been described elsewhere [13] and consist of hydrophobic and cationic amino acids that are arranged in a characteristic array to form separate and distinct hydrophobic and cationic surfaces. The human cathelicidin C-terminal peptide of CAP18 (LL-37) has been isolated from degranulated human neutrophils [14] , indicating that it is cleaved from holo-CAP18. The antibacterial and antiendotoxic activity of the Cterminal peptides differ between species [15] . Although the exact amino acid sequences are different, CAP18 shares properties with several other naturally occurring proteins that bind to LPS with high affinity, including polymyxin B [16] [17] [18] , anti-LPS factors from the amoebocytes of horseshoe crabs, Limulus polyphemus [19] and Tachypleus tridentatus [20] , LPS-binding protein (LBP) [21] , and bactericidal permeability increasing protein (BPI) [22] [23] [24] .
Two factors might limit the therapeutic potential of synthetic peptides that mimic the LPS-binding domain of cationic antibacterial peptides. The first is their expected short half-life within the circulation, due to their small size, and the second is their potential renal toxicity due to their cationic nature. We created chemical constructs consisting of the LPS-binding domain of rabbit CAP18 (CAP18 106-138 ) coupled to human IgG or purified Fc fragments, as a first attempt to develop an immunoglobulin construct that binds and neutralizes LPS from multiple gramnegative bacteria. We chose to use the rabbit CAP18 C-terminal peptide because, in preliminary studies, it was considerably more potent in binding and neutralizing LPS than was LL37. We reasoned that such a construct should have the advantage of increasing the half-life of the CAP18, as well as keeping the cationic peptide from being filtered by the kidneys. In addition, such a construct would take advantage of the Fc component of the compound as a potential means of increasing the clearance of LPS or released membrane blebs containing LPS and outer membrane proteins [25] . We found that CAP18 106-138 -IgG bound LPS from multiple bacteria, neutralized the biological activity of lipid A, and was bactericidal for multiple Enterobacteriacea [26, 27] . The present study was conducted to evaluate the protective efficacy of the constructs, in an infection model of gram-negative sepsis.
MATERIALS AND METHODS
Preparation of CAP18 106-138 and CAP18 106-138 -IgG. CAP18 106-138 was synthesized essentially as described elsewhere [28] . Peptides were synthesized by 9-fluorenylmethoxycarbonyl (FMOC) solid-state peptide chemistry, by use of automated peptide synthesizers (Exel; MilliGen/Millipore, and PS3; Rainin Instrument). Coupling was performed by use of a 5-fold molar excess of FMOC-amino acid, compared with the amount of resin, with either benzotriazole-1-yl-oxy-tris-[dimethylamino]-phosphoniumhexafluorophosphate or benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate, as activators of carboxyl residues. Reagents were purchased from NovaBiochem and Bachem. FMOC-tryptophan[t-butoxycarbonyl] (NovaBiochem) was used for the coupling of tryptophan because the peptide contains arginine. Peptides were cleaved from the resin by reagent R (90% trifluoroacetic acid, 5% thioanisole, 3% dithioethane, and 2% anisole) for 2-4 h at room temperature. Crude peptides were precipitated from reagent R by use of cold ethyl ether, then were washed twice with the same ether, were air-dried, and were dissolved in distilled water. Peptides were purified to homogeneity by reverse-phase high-pressure liquid chromatography, on 300-Å wide-bore C18 preparative columns. The amount of peptide was quantified by dry-mass or by quantitative amino-acid analyses. For subsequent coupling, a cysteine was added to the C-terminal end of the peptide [26] .
CAP18 106-138 -IgG was coupled to human IgG (Gamimune N; Bayer) by use of the heterobifunctional agent 4-Succinimidyloxyycarbonyl-methyl-[2-pyridyldithio]toluene (SMPT; Pierce Endogen), essentially according to the manufacturer's directions and as described elsewhere [29] . Pyrogen-free precautions were observed throughout. In brief, 50 mg/mL IgG was diluted to 10 mg/mL by use of pyrogen-free water and was dialyzed against PBS/EDTA (20 mM sodium phosphate, 150 mM NaCl, and 5 mM EDTA [pH 7.2]) to remove the reducing sugar maltose. A 3.5-fold molar excess of SMPT (20 mM in acetonitrile, freshly made) was added 1 drop at a time to the PBS/ EDTA-dialyzed IgG, with gentle vortexing, after which the sample was allowed to incubate for 90 min at room temperature, with slow, end-over-end rotation, to allow formation of an amide bond between the SMPT and the IgG. The reaction was quenched with 10 mL of TBS (50 mM Tris and 154 mM NaCL; [pH 8.8])/5 mg of IgG. The free SMPT was removed by extensive dialysis against PBS/EDTA (pH 6.5), after which the A280 and A343 ratios of 50 mL of SMPT-coupled IgG in 350 mL of carbonate buffer were measured. The degree of SMPT coupling was determined by adding 20 mL of 50 mM dithiothreitol (DTT). After 10 min, the A343 ratio was measured again. The concentration of 2-Py-S released after reduction was calculated according to the following formula: [2- compared with the total number of coupling groups. A 3.5-fold molar excess of SMPT, compared with human IgG, typically resulted in ∼2 SMPT groups/IgG. Sham-coupled IgG was generated by adding an equivalent amount of pyrogen-free water in place of the peptide solution. The degree of thiol-disulfide exchange was estimated by measuring the A343 ratio of the reaction mixture after incubation with peptide for 18 h at room temperature, to calculate the [2-Py-S] displaced by peptide [30] . The number of uncoupled 2-Py-S groups remaining on the peptide-IgG conjugate was measured by observing the change in the A343 ratio after adding DTT, as above. Unreacted SMPT was quenched by making the solution 2 mM cysteine and incubating it for 2 h at room temperature, with slow, end-overend rotation. Conjugates were extensively dialyzed against PBS/EDTA (pH 7.2) and then against PBS1 (10 mM sodium phosphate and 500 mM NaCl [pH 7.2]). The final product was filtered at 0.2 mM acrodisc (Gelman Sciences), and the protein concentration was determined by absorbance at 280 nm. Preparation of CAP18 106-138 -Fc. Fc fragments were purified from polyclonal human IgG. Human IgG (5%; 1g at 50 mg/mL) (Gamimune N; Bayer) was passed through a Sephadex G-25 column equilibrated with 20 mM sodium phosphate and 10 mM EDTA buffer (pH 7.1). The eluted IgG (35 mL) was combined with 50 mL of immobilized papain gel slurry (Pierce) and 85 mL of digestion buffer (20 mM phosphate, 20 mM cysteine-HCl, and 10 mM EDTA [pH 7.1]) and gently rocked overnight at 37ЊC. The recovered solution (∼154 mL) was affinity purified on a Protein G column (∼16 mL gel with a capacity of 20 mg IgG/mL gel) (Amersham Pharmacia Biotech) at 4ЊC, in 3 separate injections of equal volume. The bound Fc and undigested IgG from each injection was desorbed at low pH (0.1M glycine buffer [pH 2.5]), was neutralized with Tris buffer (1.0 M Tris [pH 8.0]), was pooled, and was concentrated to ∼17 mL in Centricon-Plus 20 concentration units (Millipore). The Fc fragment in this concentrated solution was separated on a Superose 12 column (Amersham Pharmacia Biotech) in PBS2 (15 mM sodium phosphate and 150 mM NaCl [pH 7.2]), in 2 separate injections. Fractions were pooled, were concentrated (to ∼6.5 mL), and were subjected to further purification on a Q Sepharose anion exchange column ( cm). The bound Fc fragment was 1 ϫ 15 eluted with a linear gradient of solution A, containing 20 mM tris (pH 8.1), and solution B, containing solution A plus 500 mM NaCl (0-20% solution B in 90 min and 20%-100% solution B in 15 min) at 4 mL/min. Twelve 12-mL fractions, starting at ∼60 min, were collected. Analysis of the Fc fragment after anion exchange by SDS-PAGE (12.5% gels) revealed a single band of ∼50 kDa, under nonreducing conditions, and a predominantly single band of ∼27 kDa, under reducing conditions. Faint bands were observed at ∼23 kDa and at the front (small peptides !10 kDa).
The Fc recovered from the anion-exchange column was concentrated and reequilibrated with PBS2 by use of PD-10 (buffer exchange) columns (Amersham Pharmacia Biotech). A 10-fold molar excess of the crosslinker Sulfo-Sulfosuccinimidyl 4-[Nmaleimidomethyl] cyclohexane carboxylate (SMCC; Pierce) was added to the solution and was reacted for 30 min at 37ЊC. Excess crosslinker was removed by use of PD-10 columns. The ratio of maleimide groups per Fc molecule was determined by assaying maleimide concentration with SAMSA fluorescein (5-(2-(and-3)-S(acetylmercapto)succinoyl)-amino)fluorescein; Molecular Probes), and Fc concentration was determined by UV absorption measurements at 280 nm. The Fc-sulfo-SMCC solution in PBS (pH 7.2) was divided equally: 1 portion was reacted with CAP18 106-138 at a 2-fold molar excess, compared with the number of measured maleimide groups, and the remaining portion was reacted with cysteine (sham coupled). Both the CAP18 106-138 -Fc and sham control were subsequently purified on a Superose 12 column and were analyzed by SDS-PAGE (12.5% gels), under nonreducing conditions. These showed a narrow single band slightly greater than 50 kDa and a broader band /group) was administered intravenously (iv) after C3H/HeN mice had been subjected to CLP. spanning the molecular weight (MW) range of 50-65 kDa, respectively. Under reducing conditions, the control conjugate appeared as 2 bands: 1 slightly greater than 50 kDa, and the other slightly greater than 25 kDa. The CAP18 106-138 -Fc also appeared as 2 broader bands: 1 spanning the MW range of 50-65 kDa, and the other spanning the MW range of 25-40 kDa.
Cecal ligation and puncture (CLP) model of sepsis. The protective efficacy of CAP18 (106-138) -IgG was studied in a CLP model of sepsis, in 20-25-g male C3H/HeN (Charles River Labs) and C3H/HeJ (Jackson Laboratory) mice [31] [32] [33] . Mice were maintained in a temperature-controlled room with a 12-h light control cycle and were acclimated 48 h before the operations. Throughout the course of the experiment, mice were permitted free access to water and standard food. Mice were anesthetized with intraperitoneal (ip) injections of 5 mL/g ketamine/xylazine (9 mg/mL ketamine and 1 mg/mL xylazine, in 0.9% sodium chloride). The abdomen was shaved and was washed with iodine and 70% ethanol. Via a midline laparotomy incision, the cecum was located and ligated by use of 4.0 silk, just distal to the ileocecal junction. For C3H/HeN mice, a 19-gauge needle was passed through both walls of the cecum, distal to the ligature; for C3H/ HeJ mice, 1 wall was punctured with a 19-gauge needle, and the other was punctured with an 18-gauge needle, to achieve the same mortality as in the C3H/HeN mice. After a small amount of fecal matter was expressed through each puncture site, the cecum was returned to the peritoneal cavity, and the abdomen , log-rank test). P p .96 was closed in layers by use of 4.0 chromic and 4.0 silk sutures for the fascia and skin, respectively. Immediately after the procedure, a saline bolus (20 mL/kg) was administered subcutaneously, to provide resuscitation, and CAP18 106-138 -IgG or Sham IgG (20 mg/kg) was administered intravenously (iv). Buprenorphine (0.02 mg/kg) was administered every 8 h for the first 24 h then every 12 h for the next 24 h. Animals were monitored postoperatively, every 8 h for the initial 24 h then every 12 h for the next 24 h. Mortality was monitored postoperatively for 72 h, at which time survivors were killed by CO 2 asphyxiation. Blood was obtained for culture by sterilizing the tail with 70% ethanol and cutting it by use of aseptic conditions, at 24, 48, and 72 h. In a separate experiment, mice were killed at 24 h, blood was harvested by cardiac puncture, and bacterial types were identified. Guidelines of the US Department of Health and Human Services and/or those of the authors' institutions were followed in the animal studies.
ELISAs. Direct ELISAs were performed in a manner similar to that described elsewhere [34] . Microtiter plates were coated with 2 mg/mL goat anti-human IgG (Cappel) in PBS2 and were incubated for 2 h at 37ЊC. After the plates were washed with wash buffer (15 M sodium phosphate, 150 mM sodium chloride, 2 mg/mL magnesium chloride, 0.1% Tween-20, and 1 mg/mL bovine serum albumin [BSA] [pH 7.2]), dilutions of either serum of mice subjected to CLP obtained at various time points or human IgG (2-2000 ng/mL; Cappel) in PBS-BSA (PBS2; 1 mg/mL BSA) were added (100 mL/well), and the plates were incubated overnight at 4ЊC. After further washing, a 1: 5000 dilution of alkaline phosphatase-conjugated anti-human IgG (Cappel) in PBS-BSA was added (100 mL/well), and the plates were incubated for 2 h at 37ЊC. The plates were again washed, ending with a final wash with DEA buffer (1 M diethanolamine and 0.05 mM MgCl 2 [pH 9.8]). Alkaline phosphatase substrate (p-nitrophenylphosphate; Sigma) was added (1 mg/mL in DEA buffer), and the mixture was incubated for 30 min at room temperature, after which the plates were read at 405 nm on an ELISA reader (EAR 400; SLT Lab Instruments). All assays were performed in duplicate, and the optical densities were averaged. IgG values were determined on the basis of the standard curve, by use of the method of Zollinger and Boslego [35] .
Bacteria, MIC assays, and LPS. Bacterial isolates were identified from both sham IgG-and CAP18 106-138 -IgG-treated blood from mice subjected to CLP, at 24 h. Mice were killed at 24 h, and cardiac blood was obtained in a sterile fashion. Isolator tubes (Wampole) containing ∼1 mL of freshly collected blood were sent to the Massachusetts Eye and Ear Infirmary Bacteriology Laboratory. The blood was inoculated into Brucella blood agar, with 5% horse blood (BAP; Becton Dickinson), chocolate agar (Remel), MacConkey agar (Remel), and cooked-meat medium (CM; Remel). The plates were incubated in 3%-10% C0 2 for a minimum of 48 h at 35ЊC. The CM was incubated in ambient atmosphere for 1 week at 35ЊC. Media were examined daily for growth. Colonies were gram stained and were isolated to BAP for purity. Most gram-negative isolates were identified by use of the Micro-ID system (Remel). Nonenteric gram-negative rods were identified by use of a gram-negative Microscan panel (Dade Behring). Gram-positive cocci were identified by use of a grampositive Microscan panel.
Microdilution MIC assays were performed as described by the NCCLS, with some modification. In brief, bacteria from 24-h growth on typtic soy agar (Becton Dickinson) and plate cultures were suspended in sterile saline and were adjusted to absorbance at 625 nm of 0.08-0.1. This solution was diluted 1:100 in tryptic soy broth (TSB; Becton Dickinson). Two-fold dilutions of 1 mg/mL CAP18 106-138 peptide were made in TSB. Ninety-six-well microtiter plates were loaded with 50 mL each of the peptide solution and bacterial innoculum, to provide ∼ cfu/well. Plates were read at 550 nm on an ELISA plate reader. The MIC was determined as that concentration with an optical density matching the zero-growth broth control.
Radiolabeled LPS was extracted from E. coli O25 (gift of Alan Cross, University of Maryland Cancer Center, Baltimore) that had been biosynthetically radiolabeled by growth, in the presence of 3 H-acetate (Du Pont; New England Nuclear), as described elsewhere [7] . Specific activity of this LPS was 5300 cpm/mg. LPS was purified from bacteria isolates from mice subjected to CLP, as described by Rudbach et al. [36] , by use of the hot-phenol method [37] .
Immunoblotting. Assorted LPSs extracted from bacterial isolates obtained from mice subjected to CLP were electrophoresed and were blotted onto polyvinylidene fluoride (PVDF) membrane. The ability of the conjugate to bind to LPS in the solid phase was assessed by incubating CAP18 106-138 -IgG with the PVDF and then developing it with reagents, to detect bound IgG. Fourteen micrograms of LPS was electrophoresed in a 16%-polyacrylamide gel, under reducing conditions, and transferred to PVDF (200 mA; constant current; 1 h), by use of a transfer apparatus. The PVDF was blocked overnight with 10% skim milk in casein buffer (9 mM sodium phosphate, 90 mM sodium chloride, 30 mM sodium hydroxide, 10 mg/mL casein, and 1.5 mg/mL BSA [pH 7.4]), was washed ( min 3 ϫ 10 Tris-Tween buffered saline (TTBS) [300 mM sodium chloride, 50 mM tris, 0.2% Tween-20, and 3 mg/mL BSA /pH 7.5/]), and then was incubated with 2.5 mg/mL CAP18 106-138 -IgG in TTBS for 1 h. The blots were washed 3 times in TTBS, and the PVDF was incubated with biotinylated anti-human IgG (1: 240 in TTBS) (Vectastain; Vector Laboratories) for 30 min. After 3 additional washes, the blots were incubated with avidinbiotinylated horseradish peroxidase complex for 30 min and were washed again. After a final PBS wash, peroxidase substrate was added (2 mL of 3 mg/mL 4-chloro-1-naphthol in methanol, 8 mL of PBS, and 10 mL of 30% H 2 O 2 ). The reaction was stopped after 30 min by repeated rinsing with distilled water.
Fluid-phase LPS-binding competition radioimmunoassay. To examine the fluid-phase interaction of CAP18 106-138 -IgG with the LPS extracted from bacterial isolates from mice subjected to CLP, we adapted a competition radioimmunoassay [27] using magnetic beads covalently coupled to rabbit anti-human IgG. Anti-human IgG (Jackson Immunoresearch Laboratories) was coupled to magnetic beads (BioMag Amine Terminated 8-4100; Per Septive Diagnostics), according to the manufacturer's directions and as described elsewhere [27] . All beads were extensively washed with PBS2 and were resuspended in PBS2 (1% BSA) just before being used. CAP18 106-138 -IgG and dilutions of cold LPS were combined, to a total volume of 196 mL of PBS2. Four microliters of 100 mg/mL 3 H O25 E. coli LPS was then added to make the final concentrations 6 mg/mL CAP18 106-138 -IgG, 0.39-1600 mg/mL cold LPS, and 2 mg/mL 3 H O25 E.coli LPS. Tubes were vortexed and were incubated for 30 min at 37ЊC, with slow, end-over-end rotation. Six hundred microliters of a solution containing anti-human IgG magnetic beads (sufficient to bind all the human IgG, as determined by ELISA) in PBS2 (1% BSA) were added and were incubated overnight at 4ЊC, to capture the CAP18 106-138 -IgG conjugate and bound LPS. On the next day, after vortexing, the samples were placed in a strong magnetic field (magnet obtained from Perceptive Diagnostics) to separate beads containing captured CAP18 106-138 -IgG and bound 3 H-LPS, from unbound 3 H-LPS, in solution. While still applied to the magnet, the supernatant was carefully aspirated and was set aside. The beads were then washed 4 times by removal of the magnet, addition of PBS2, vortexing, and reapplication of the magnet. After washing the magnetic beads, 290 mL of 0.1% SDS solution was added to 30 mL of beads and was incubated for 1 h at 37ЊC, to cleave the 3 H-LPS from the beads. The beads were then applied to the magnet, and the remaining solution containing eluted 3 H-LPS was removed. The supernatant and the SDS bead elution were then counted for the presence of tritium, by use of liquid-scintillation counting. Percentage capture was calculated as follows: counts per minute (cpm) bead elution/(cpm bead elution + cpm supernatant); percentage recovery was calculated as follows: (cpm bead elution + cpm supernatant)/total cpm added. In all experiments, there was 175% recovery.
Actinomycin D-sensitized mouse model. This assay was performed as described elsewhere [9] , by use of the method of Pieroni et al. [38] . In brief, C3H/HeN mice were injected iv with 100 mL of 4.5 mg/mL sham IgG or 4.5 mg/mL CAP18 (106-138) -IgG. E. coli O111:B4 LPS in pyrogen-free saline or saline alone were combined 1:1 with 500 mg/mL actinomycin D. This solution was injected ip 5 min after the injection of either CAP18 (106-138) -IgG or sham IgG. All mice received 22.5 mg IgG or 22.5 mg CAP18 106-138 -IgG or saline, 25 mg actinomycin D, and dilutions of LPS or saline.
Statistics. Data were analyzed by log-rank test, 2-tailed unpaired t test, and 2-sided Fisher's exact test on GraphPad Prism (version 3.02; GraphPad Software).
RESULTS

Pharmacokinetics of CAP18 106-138 -IgG.
On the basis of previous studies, we estimated that, in normal mice, a dose of 20 mg/kg CAP18 106-138 -IgG would lead to initial serum concentrations of human IgG of 50-100 mg/mL. Levels of 1.0 mg/mL O-chain-specific anti-LPS IgG are protective in a neonatal rat model [39] . To establish a basis for dosing in the CLP model, in a pilot study, we measured, in small numbers of mice subjected to CLP, human IgG, by ELISA, at various time points after iv administration of either CAP18 106-138 -IgG or shamcoupled human IgG (20 mg/kg). These results are shown in figure 1 . Levels of CAP18 106-138 -IgG were significantly lower at 30 min ( , t test), but not at later time points, up to P p .043 72 h. Levels of both CAP18 106-138 -IgG and sham-coupled IgG remained 120 mg/mL over the course of the experiment.
Protective efficacy of CAP18 106-138 -IgG in CLP model. We next studied, in inbred C3H/HeN mice, the protective efficacy of a single dose of 20 mg/kg CAP18 106-138 -IgG administered immediately after CLP. These results are shown in figure 2A . Survival was significantly increased in the group that received CAP18 106-138 -IgG ( /group; , log-rank test). n p 32 P ! .03 In a subsequent set of experiments, we used the same model to study the efficacy of 20-mg/kg dose of a similar conjugate prepared using purified Fc fragments, CAP18 106-138 -Fc. CAP18 106-138 -Fc resulted in a strong trend toward survival ( -13/group; , log rank test) (figure 2B). n p 12 P ! .06 To study the contribution of the IgG moieties of the CAP18 constructs to the protective efficacy of CAP18 106-138 -IgG, we repeated these experiments using equimolar concentrations of CAP18 106-138 peptide alone (1.2 mg/kg peptide). CAP18 106-138 peptide did not reduce mortality ( figure 3) .
Bacteriology. The protection provided could theoretically be provided either by the bactericidal properties of CAP18 106- ). There were also more mice with colony counts 199 cfu .02 in the sham IgG group than in the CAP18 106-138 -IgG group (6 mice vs. 1 mouse, respectively;
). P p .01 A separate experiment was designed to determine whether treatment of mice subjected to CLP, with CAP18 106-138 -IgG, had a major effect on the types of organisms identified in the blood. Groups of 11 mice were treated with CAP18 106-138 -IgG or shamcoupled IgG. Bacterial isolates were identified from positive blood cultures obtained 24 h after CLP. These results are shown in table 1. Nine of the CAP18 106-138 -IgG group and 6 of the sham IgG group survived to 24 h. The predominant gramnegative organisms identified were E. coli, Proteus mirabilis, and Pseudomonas aeruginosa.
We noted that, in many mice, there were particularly high colony counts of certain bacterial species, with a similar colony morphology. Accordingly, in a separate experiment, 6 colony types that were present in high colony counts were randomly chosen for identification and further study. Three strains were P. mirabilis with different biotypes, 2 were E. coli with different biotypes, and 1 was Klebsiella oxytoca. To determine whether the high colony counts of these strains were due to breakthrough bacteremia from strains that were sensitive to CAP18 106-138 -IgG or were due to bacteremia from strains that were resistant to the construct, we measured the MIC of each strain to the peptide itself. These data are shown in table 2. The MIC was higher for the 3 P. mirabilis strains than for either the E. coli or the K. oxytoca strains (1250 vs. 15.6 mg/mL, respectively).
Binding of CAP18 106-138 -IgG to LPS. Because CAP18 106-138 -IgG failed to inhibit growth of 3 Proteus strains, it was of interest to evaluate its binding to the LPS of these strains. LPS was extracted from the 6 strains described above that were isolated in high colony counts from mice subjected to CLP. Binding to these LPSs, as well as to a commercially acquired control LPS, was studied by Western blotting. CAP18 106-138 -IgG bound to the LPS from both E. coli and K. oxytoca but not to LPS from any of the Proteus strains (figure 5). Binding of the CAP18 106-138 -IgG to LPS was also studied in a fluid-phase format, by use of a competition radioimmunoassay. We used a competition radioimmunoassay in which binding of CAP18 106-138 -IgG to tritiated LPS from E. coli O25 was determined in the presence of varying concentrations of unlabeled LPS that previously had been extracted from the bacterial strains of interest. These results, shown in figure 6 , indicate that unlabeled LPS from E. coli competed for binding for CAP18 106-138 -IgG in roughly equimolar concentrations. LPS extracted from all 3 strains of P. mirabilis competed poorly for binding.
Role of anti-LPS activity of CAP18 106-138 -IgG in its protective efficacy. To evaluate the anti-LPS activity of CAP18 106-138 -IgG in vivo, we studied the protective efficacy of CAP18 106-138 -IgG (20 mg/kg) in mice that had been sensitized to LPS by use of actinomycin [38] . Mortality was lower in the CAP18 106-138 -IgG group, compared with that in the control sham-coupled human IgG group (figure 7).
To attempt to distinguish the relative protective roles for the antibacterial and anti-LPS properties of CAP18 106-138 -IgG in the CLP model, we studied the protective efficacy of CAP18 106-138 -IgG in C3H/HeJ mice. These mice are hyporesponsive to LPS, on the basis of a point mutation in the gene for Toll-like receptor 4 (TLR-4) [40] . There was a trend toward increased survival in mice that had received CAP18 106-138 -IgG ( ) P p .06 ( figure 8 ). These data support the notion that, in this model, the protection of CAP18 106-138 -IgG is not mediated only by an anti-LPS activity.
DISCUSSION
The major finding of the present study is that a chemically created conjugate of an LPS-binding peptide coupled to IgG protects in a well-established model of infection that leads to polymicrobial bacteremia, sepsis, and death. The peptide that we used for study, rabbit CAP18 106-138 , mimics the LPS-binding domain from the rabbit leukocyte protein of 18 kDa, CAP18. This peptide, as well as the protein, has antibacterial activity, in addition to LPS-binding and -neutralizing activity. The peptide is hydrophobic and cationic and shares properties (but not sequences) with numerous other antibacterial proteins that bind to the outer membrane of gram-negative bacteria. These include, but are not limited to, BPI [22] [23] [24] , LBP [21] , Limulus anti-LPS factor [19] , polymyxin B [16] [17] [18] , and other cationic proteins in neutrophils [41, 42] .
Previous investigators have coupled short peptides, such as polymyxin B, to dextran [43] and IgG [44] , with the goal of decreasing toxicity and increasing the serum half-life of polymyxin B. These agents were demonstrated to bind LPS and provide some protection in galactosamine-sensitized mice that had been challenged with iv LPS [44] or bacteria in conjunction with antibiotics [43] . Our data extend these findings in several ways. First, our results suggest that short peptides of mammalian origin coupled to IgG will bind and neutralize LPS. This is important, because it paves the way for the creation of recombinant versions of CAP18 106-138 -IgG. Second, our results indicate that CAP18 106-138 -IgG protects in an established model of polymicrobial infection that mimics common forms of sepsis due to a ruptured abdominal organ in humans. Third, our results indicate that constructs such as CAP18 106-138 -IgG function in vivo as an antibiotic. In the CLP model, twice as many surviving mice that had received CAP18 106-138 -IgG had sterile blood cultures than mice that had received the IgG control.
Although LPS is highly toxic, the role that it plays in the pathophysiology of gram-negative bacterial infections is unknown. Because most of the cationic hydrophobic peptides that bind and neutralize LPS also have antimicrobial activity, it has not been clear whether their potential protective activities are due to their antiendotoxic properties or to their antibiotic properties. Two aspects of our experiments suggest that the antimicrobial activity of the conjugate may be important for the protection observed. First, in addition to protection in C3H/ HeN mice, there was statistically significant protection in C3H/ HeJ mice, a strain that is markedly resistant to the effects of LPS because of a mutation in the TLR-4 gene. If the anti-LPS activities accounted for all the protection observed, there should have been no protection in mice that were not sensitive to LPS. and , respectively) was administered intravenously after C3H/HeJ mice had been subjected to CLP. n p 28 n p 27 Mice treated with CAP18 106-138 -IgG had a trend toward increased survival ( , log-rank test). P p .062
Second, there was a striking alteration in the blood cultures of mice that had been treated with CAP18 106-138 -IgG.
An unexpected finding that emerged from the microbiological studies was that there was an abundance of Proteus species in blood cultures of mice that had received CAP18 106-138 -IgG. Further testing revealed that these strains were P. mirabilis and that the 3 strains that were examined were highly resistant to the antibiotic activity of CAP18 106-138 peptide. The resistance was mediated by decreased binding of CAP18 106-138 -IgG to the LPS from the 3 Proteus strains. Resistance of Proteus strains to other antimicrobial peptides, such as polymyxin B, as well as to CAP18, has been described elsewhere [45] , although the clinical significance of this resistance, in relation to innate immunity, is unclear. The present study has suggested that resistance among Proteus species could be a problem if CAP18 106-138 -IgG were to be developed and used as therapy for sepsis of abdominal origin.
Our study has indicated that it is possible to convert antimicrobial peptides that are ineffective by themselves into antimicrobial immunoglobulins that are therapeutically effective for sepsis, by chemically coupling the peptides to IgG. The same approach should also be feasible by using a genetic approach to create peptide-immunoglobulin fusion proteins.
